Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The alpha interferons: clinical overview.

R J Spiegel

    Seminars in Oncology
    |June 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Recombinant alpha interferons offer insights into biological compound development, with dose-response and schedule dependence being key factors. Safety profiles show manageable toxicities, but antibody development requires further study.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Technical assessment of fuel cell operation on anaerobic digester gas at the Yonkers, NY, wastewater treatment plant.

    Waste management (New York, N.Y.)·2003
    Same author

    Biologic therapy of cancer.

    New Jersey medicine : the journal of the Medical Society of New Jersey·1990
    Same author

    Alpha interferons: 1989.

    Cancer investigation·1990
    Same author

    Alpha interferons: a clinical overview.

    Urology·1989
    Same author

    Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.

    Journal of interferon research·1989
    Same author

    Comparison of finite-difference time-domain SAR calculations with measurements in a heterogeneous model of man.

    IEEE transactions on bio-medical engineering·1989
    Same journal

    A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

    Seminars in oncology·2026
    Same journal

    Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

    Seminars in oncology·2026
    Same journal

    PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

    Seminars in oncology·2026
    Same journal

    Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

    Seminars in oncology·2026
    Same journal

    Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

    Seminars in oncology·2026
    Same journal

    Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

    Seminars in oncology·2026
    See all related articles

    Area of Science:

    • Biotechnology
    • Pharmacology
    • Oncology

    Background:

    • Recombinant alpha interferons serve as a model for biological compound development.
    • Over 5,000 patients have been treated, yielding valuable clinical data.

    Purpose of the Study:

    • To review current safety, efficacy, and neutralizing antibody data for alpha interferons.
    • To discuss implications for phase I-II strategies for other biologicals.

    Main Methods:

    • Clinical data analysis from over 5,000 patients treated with alpha interferons.
    • Review of reported safety, efficacy, and antibody development studies.

    Main Results:

    • Dose-response relationships and schedule dependence are suggested.

    Related Experiment Videos

  • Fever, flu-like symptoms, and CNS effects are common toxicities; hematologic and GI toxicities are generally mild and reversible.
  • Antibody and neutralizing factor development occurs occasionally, with significance yet to be determined.

    • Conclusions:

    • Alpha interferons provide a prototype for biological drug development, highlighting critical factors like tumor burden and patient subtypes.
    • Further research is needed to fully elucidate the role of alpha interferons and the implications of neutralizing antibodies.